Integrin α5β1 promotes survival of growth-arrested breast cancer cells:: An in vitro paradigm for breast cancer dormancy in bone marrow

被引:112
作者
Korah, R [1 ]
Boots, M [1 ]
Wieder, R [1 ]
机构
[1] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Hematol Oncol, Newark, NJ 07103 USA
关键词
D O I
10.1158/0008-5472.CAN-03-3853
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanisms of long-term survival of occult breast cancer cells in the bone marrow microenvironment are not known. Using selected bone marrow stromal components with demonstrated roles in promoting growth arrest and survival of breast cancer cells, we reconstituted an in vitro model for dormancy of breast cancer cells in bone marrow. According to this model, basic fibroblast growth factor, a mammary differentiation factor abundant in the bone marrow stroma, induces growth arrest of relatively well-differentiated breast cancer cells, induces a spread appearance, and restricts their survival to fibronectin by up-regulating integrin alpha5beta1. Most of the basic fibroblast growth factor-arrested cells fail to establish optimal ligation to fibronectin and undergo cell death. Cells that do attach to fibronectin, another major constituent of the bone marrow microenvironment, stay alive and growth-arrested for many weeks. Although capable of adhering to other stromal proteins collagen and laminin, dormant cells do not gain a survival advantage from these interactions. Using function-blocking peptides, we show a specific contribution of alpha5beta1-fibronectin interaction in maintaining survival of growth-arrested cells, potentially by negatively modulating apoptotic response via signaling pathways. Blocking of phosphatidylinositol 3'-kinase and Akt inhibits survival of dormant clones, demonstrating this as one of those pathways. Experiments with human bone marrow stroma cocultures confirm the role of fibronectin ligation in maintaining survival of dormant clones.
引用
收藏
页码:4514 / 4522
页数:9
相关论文
共 37 条
[1]   Urokinase receptor and fibronectin regulate the ERKMAPK to p38MAPK activity ratios that determine carcinoma cell proliferation or dormancy in vivo [J].
Aguirre-Ghiso, JA ;
Liu, D ;
Mignatti, A ;
Kovalski, K ;
Ossowski, L .
MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (04) :863-879
[2]   COMPARATIVE EXPRESSION OF FIBROBLAST GROWTH-FACTOR MESSENGER-RNAS IN BENIGN AND MALIGNANT BREAST DISEASE [J].
ANANDAPPA, SY ;
WINSTANLEY, JHR ;
LEINSTER, S ;
GREEN, B ;
RUDLAND, PS ;
BARRACLOUGH, R .
BRITISH JOURNAL OF CANCER, 1994, 69 (04) :772-776
[3]   Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells [J].
Aoudjit, F ;
Vuori, K .
ONCOGENE, 2001, 20 (36) :4995-5004
[4]   Factors regulating the growth of metastatic cancer in bone [J].
Boyce, BF ;
Yoneda, T ;
Guise, TA .
ENDOCRINE-RELATED CANCER, 1999, 6 (03) :333-347
[5]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[6]   Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients [J].
Braun, S ;
Kentenich, C ;
Janni, W ;
Hepp, F ;
de Waal, J ;
Willgeroth, F ;
Sommer, H ;
Pantel, K .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :80-86
[7]  
Brunell Mark S., 1993, Plant Species Biology, V8, P1, DOI 10.1111/j.1442-1984.1993.tb00228.x
[8]   PHOSPHOLIPASE-C RELEASE OF BASIC FIBROBLAST GROWTH-FACTOR FROM HUMAN BONE-MARROW CULTURES AS A BIOLOGICALLY-ACTIVE COMPLEX WITH A PHOSPHATIDYLINOSITOL-ANCHORED HEPARAN-SULFATE PROTEOGLYCAN [J].
BRUNNER, G ;
GABRILOVE, J ;
RIFKIN, DB ;
WILSON, EL .
JOURNAL OF CELL BIOLOGY, 1991, 114 (06) :1275-1283
[9]  
BRUNNER G, 1994, BLOOD, V83, P2115
[10]   Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer [J].
Chang, J ;
Powles, TJ ;
Allred, DC ;
Ashey, SE ;
Clark, GM ;
Makris, A ;
Assersohn, L ;
Gregory, RK ;
Osborne, CK ;
Dowsett, M .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (10) :3058-3063